How to monitor SLE in routine clinical practice

Annals of the Rheumatic Diseases

Volumn 64, Issue 4, 2005, Pages 524-527

  Fernando, M M A ^a   Isenberg, D A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; AZATHIOPRINE; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4D; DNA ANTIBODY; DOUBLE STRANDED DNA; METHOTREXATE;

ANTIBODY TITER; CLINICAL FEATURE; CLINICAL PRACTICE; COMPLEMENT SYSTEM; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DRUG MONITORING; HEALTH CARE PERSONNEL; HEALTH STATUS; HUMAN; KIDNEY FUNCTION; LABORATORY TEST; LIVER FUNCTION; OSTEOPOROSIS; PATIENT MONITORING; PREGNANCY; PRIORITY JOURNAL; REVIEW; SEROLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; FEMALE; HEALTH STATUS INDICATORS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; OSTEOPOROSIS;

EID: 16344385083     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2003.015248     Document Type: Review

References (12)

1. Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, et al. The BILAG index: a reliable and valid instrument of measuring clinical disease activity in systemic lupus erythematosus. QJ Med 1993;86:447-58.
2. Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P. Outcome measures to be used in clinical trials in SLE. J Rheumatol 1999;26:490-8.
3. Gladman DD, Urowitz MB, Goldsmith C, Fortin P, Ginzler E, Gordon C, et al. Assessment of the reliability of the Systemic Lupus Collaborating Clinics/ American College of Rheumatology damage index in patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:809-13.
4. Stoll T, Seifert B, Isenberg DA. SLICC/ACR damage index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with SLE. Br J Rheumatol 1996;32:248-54.
5. Rahman P, Gladman DD, Urowitz MB, Hallett D, Tam LS. Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. Lupus 2001;10:93-6.
6. Stall T, Gordon C, Seifert B, Richardson K, Malik J, Bacon PA, et al. Consistency and validity of patient administered quality of life by MOS-SF36, its association with disease activity and damage in patients with systemic lupus erythematosus. J Rheumatol 1997;24:1608-14.
7. Wang C, Mayo NE, Fortin P. The relationship between health related quality of life and disease activity and damage in systemic lupus erythematosus. J Rheumatol 2001;28:525-32.
8. Walz le Blanc BA, Gladman D, Urowitz MB. Serologically active clinically quiescent systemic lupus erythematosus: predictors or clinical flares. J Rheumatol 1994;21:2239-41.
9. Morrow WJW, Williams DJP, Ferec C, Casburn-Budd R, Isenberg DA, Paice E, et al. The use of C3d as a means of monitoring clinical activity in systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis 1983;42:668-71.
10. Manzi S, Meilahn EN, Rairie J, Conte CG, Medsger TA Jr, Jansen-McWilliams L, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997;145:408-15.
11. Lakshminarayanan S, Walsh S, Mohanraj M, Rothfield N. Factors associated with low bone mineral density in patients with systemic lupus erythematosus. J Rheumatol 2001;28:102-8.
12. Haq I, Isenberg DA. How does one assess and monitor patients with systemic lupus erythematosus in daily clinical practice? Best Pract Res Clin Rheumatol 2002;16:181-94.